Ribosomal protein L22 pseudogene 16 (RPL22P16)

RPL22P16, or ribosomal protein L22 pseudogene 16, is classified as a *processed pseudogene* in the human genome[2][7][5]. It is one of several unprocessed or processed DNA copies (pseudogenes) of the functional ribosomal protein L22 (RPL22) gene, dispersed throughout the human genome as a result of gene duplication or retrotransposition events[1][4][5]. Pseudogenes typically do not encode functional proteins, lack established biological functions, and are not considered therapeutic targets, receptors, or enzymes. RPL22P16 has alternative names such as RPL22_6_780 and is listed in gene/protein databases as a non-coding pseudogene[2][7][5]. There is no evidence that RPL22P16 plays a role in disease, interacts with drugs, serves as a biomarker, or is relevant for therapeutic targeting. Information provided in databases confirms its annotation as a pseudogene and not as a functional target[2][7].

Other names

RPL22_6_780RPL22P16